Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accumulated Expenses (2016 - 2026)

Ironwood Pharmaceuticals' Accumulated Expenses history spans 16 years, with the latest figure at $771000.0 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 83.84% to $771000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $771000.0, a 83.84% decrease, with the full-year FY2025 number at $771000.0, down 83.84% from a year prior.
  • Accumulated Expenses hit $771000.0 in Q4 2025 for Ironwood Pharmaceuticals, down from $10.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for IRWD hit a ceiling of $32.0 million in Q2 2023 and a floor of $771000.0 in Q4 2025.
  • Historically, Accumulated Expenses has averaged $10.0 million across 5 years, with a median of $8.8 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: soared 700.57% in 2022 and later crashed 83.84% in 2025.
  • Tracing IRWD's Accumulated Expenses over 5 years: stood at $16.7 million in 2021, then decreased by 26.33% to $12.3 million in 2022, then crashed by 32.32% to $8.3 million in 2023, then plummeted by 42.54% to $4.8 million in 2024, then crashed by 83.84% to $771000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for IRWD at $771000.0 in Q4 2025, $10.6 million in Q3 2025, and $4.6 million in Q2 2025.